Approved trends and product characteristics of digital therapeutics in four countries
Abstract Digital therapeutics (DTx) provide innovative treatment options. In this study, we identified and compared approved DTx in China, the US, Germany, and Belgium. In total, 507 DTx applications were identified (US, 192; China, 235; Germany, 55; Belgium, 25). China has approved the most, wherea...
Saved in:
| Main Authors: | Jun Liang, Qichuan Fang, Xiaoyi Jiao, Peng Xiang, Junhao Ma, Zijiao Zhang, Yongcheng Liu, Yunfan He, Yingjun Li, Zhixu He, Jianbo Lei |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | npj Digital Medicine |
| Online Access: | https://doi.org/10.1038/s41746-025-01660-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trends and Commonalities of Approved and Late Clinical-Phase RNA Therapeutics
by: Maxime Tufeu, et al.
Published: (2025-07-01) -
Therapeutic Adherence of Patients with Type 2 Diabetes Mellitus in Four Health Areas of the Country
by: Addys María Díaz Piñera, et al.
Published: (2024-03-01) -
Comparison of generic drug prices in Korea and eight high-income countries across four therapeutic classes
by: Chanmi Park, et al.
Published: (2025-01-01) -
Unraveling the therapeutic landscape of approved non-peptide macrocycles
by: Zhonghua Li, et al.
Published: (2025-07-01) -
Suicidal behaviours among 13- to 15-year-olds in four southeast Asian countries: Trends and contributing factors
by: Thach Tran, et al.
Published: (2025-01-01)